For the year ending 2025-12-31, ORMP had -$8,473K decrease in cash & cash equivalents over the period. -$9,154K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 64,016 |
| Depreciation | 121 |
| Exchange differences and interest on deposits | -830 |
| Changes in fair value of investments | -86,096 |
| Stock-based compensation | 5,992 |
| Gain on amounts funded in respect of employee rights upon retirement | 12 |
| Prepaid expenses and other current assets | 998 |
| Accounts payable, accrued expenses and related parties | 1,130 |
| Net changes in operating lease | 117 |
| Deferred revenues | -2,000 |
| Deferred income | 105 |
| Liability for employee rights upon retirement | 9 |
| Deferred tax liabilities | -7,911 |
| Other liabilities | -60 |
| Total net cash used in operating activities | -9,145 |
| Purchase of property and equipment | 9 |
| Purchase of short-term deposits | 10,948 |
| Purchase of marketable securities | 9,846 |
| Investments at fair value | -64,712 |
| Purchase of convertible note | 3,000 |
| Proceeds from redemption of short-term deposits | 54,450 |
| Proceeds from loan to an equity method investee | 6,251 |
| Loan to investment in equity method | 7,000 |
| Real estate investment | 1,924 |
| Equity method investee | 250 |
| Proceeds from marketable securities | 2,865 |
| Proceeds from long-term investments and marketable securities | 39,566 |
| Total net cash provided by investing activities | 5,443 |
| Repurchase and retirement of common stock | 4,741 |
| Total net cash used in financing activities | -4,741 |
| Effect of exchange rate changes on cash and cash equivalents | -30 |
| Increase (decrease) in cash and cash equivalents | -8,473 |
| Cash and cash equivalents at beginning of year | 54,420 |
| Cash and cash equivalents at end of year | 45,947 |
ORAMED PHARMACEUTICALS INC. (ORMP)
ORAMED PHARMACEUTICALS INC. (ORMP)